- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
IOM report suggests ways FDA can improve drug safety
The Institute of Medicine has issued a report to Congress criticizing the FDA?s drug approval system.
The Institute of Medicine has issued a report to Congress criticizing the FDA’s drug approval system. The report offers 25 recommendations for improving drug safety. Among them is one calling for restricting the distribution of certain drugs to certain facilities, pharmacists, or physicians with special training or experience. Also, IOM recommends adding a symbol on newly approved drugs to alert consumers that long-term safety data might not be available. In response, the FDA said it would take the recommendations under advisement, but noted that many of the suggestions are already being put in place. To review the report, “The future of drug safety: Action steps for Congress,” go to http://www.iom.edu/CMS/3793/26341/37329.aspx.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
